Lupin gets $50 million from Boehringer Ingelheim as #39;milestone payment#39; for anti-cancer drug

Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.

from Moneycontrol Business News https://ift.tt/3wFaSa7